Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ralph Mazitschek
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Regenacy Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Mazitschek serves on the SAB for Regenacy Pharmaceuticals. He receives consulting income and owns equity in the privately held company. The company is developing isoform selective HDAC inhibitors for various disease indications. The research grant identified above studies the function of HDAC isoforms and HDAC inhibitors in specific mechanistic aspects of human physiology and disease. The research could potentially identify novel mechanistic aspects or develop novel inhibitors that could be of interest to the company. The institution determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity
Growing evidence points to a critical role for epigenetic mechanisms, in particular the post-translational modification of histone proteins, in diverse aspects of human health and disease ranging from cognitive disorders to cancer. The proposed studies will take an integrated, multidisciplinary approach-spanning synthetic chemistry to neurobiology-to create innovative chemical tools that can be optically controlled to provide precise spatiotemporal regulation of epigenetic mechanisms implicated in governing neuroplasticity. As an example of advancing this technology for neuromodulation, the focus will be on manipulating the enzymatic activity of histone deacetylases (HDACs) whose activity controls the expression of key genes involved in synaptogenesis and synaptic plasticity and therefore are potential targets for novel therapeutic development for a range of brain disorders.
Filed on July 31, 2017.
Tell us what you know about Ralph Mazitschek's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Ralph Mazitschek filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ralph Mazitschek | Massachusetts General Hospital | Conflict of Interest | Regenacy Pharmaceuticals | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.